Cytokines activating the Jak/STAT signaling cascade have been implicated in HCC initiation and development, and in particular IL-6 and IL-11 show encouraging results not only as potential biomarkers for liver tumors, but also as functional therapeutic targets. This evidence concerns the gene IL6 and hepatocellular carcinoma.